GreenLight HPS is designed to enable the treatment of a wide range of gland sizes, as well as for patients on anti-coagulation therapy.
AMS claims GreenLight provides treatment with fewer side effects than TURP, improving clinical outcomes and patient safety for individuals with mild to severe BPH symptoms.
The system will be offered in Japan through an exclusive distribution agreement with MC Medical, a subsidiary of Mitsubishi and a supplier of minimally invasive medical devices and supplies in Japan.
AMS vice president and GM Mike Ryan said not only this expansion strengthens AMS global presence but it also allows them to leverage MC Medical’s reputation within the Japanese urological community and its sales organization to reach academic and private medical centers throughout the country.
